Breaking News, Collaborations & Alliances

Plus Therapeutics, Piramal Pharma Solutions Expand Partnership for cGMP Drug Production

Rhenium (186Re) obisbemeda has been formulated for safe delivery of highly targeted high dose radiation in CNS tumors.

Plus Therapeutics, a clinical-stage pharmaceutical company, expanded its partnership with Piramal Pharma Solutions (PPS), a contract development and manufacturing organization (CDMO), to produce additional cGMP liposome intermediate drug products. The alliance aims to meet the rising demand for Plus Therapeutics’ lead investigational targeted radiotherapeutic, rhenium (186Re) obisbemeda, for clinical trials that are underway and planned. The latest supply agreement builds on the master ser...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters